

CLNE0029: Clinical neuroscience of neurodegenerative diseases

[View Online](#)

1.

Clarke C, Howard R, Rossor M, Shorvon SD, eds. Neurology: A Queen Square Textbook. Second edition. Wiley Blackwell; 2016.
<https://onlinelibrary.wiley.com/doi/book/10.1002/9781118486160>

2.

McCarthy RA, Warrington EK. Cognitive Neuropsychology: A Clinical Introduction. Academic Press, Inc; 1990.
http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=2909618430004761&institutionId=4761&customerId=4760

3.

Rossor M, Growdon JH. The Dementias 2. Butterworth Heinemann/Elsevier; 2007.
http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=2909618250004761&institutionId=4761&customerId=4760

4.

Hodges JR. Cognitive Assessment for Clinicians. 3 ed. Oxford University Press; 2017.
<http://dx.doi.org/10.1093/med/9780198749189.001.0001>

5.

Kandel ER, Schwartz JH, Jessell TM, Siegelbaum S, Hudspeth AJ, eds. Principles of Neural Science. Fifth edition. McGraw Hill Medical; 2013.

http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=2909605810004761&institutionId=4761&customerId=4760

6.

Husain M. Oxford Textbook of Cognitive Neurology and Dementia. (Husain M, Schott JM, Kennard C, eds.). Oxford University Press; 2016.
http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=2909605720004761&institutionId=4761&customerId=4760

7.

Alzheimer's Facts and Figures Report | Alzheimer's Association.
<https://www.alz.org/alzheimers-dementia/facts-figures>

8.

Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Molecular Medicine. 2016;8(6):595-608. doi:10.15252/emmm.201606210

9.

Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. The Lancet Neurology. 2014;13(6):614-629. doi:10.1016/S1474-4422(14)70090-0

10.

Loy CT, Schofield PR, Turner AM, Kwok JB. Genetics of dementia. The Lancet. 2014;383(9919):828-840. doi:10.1016/S0140-6736(13)60630-3

11.

Karran E, Hardy J. Anti-amyloid Therapy for Alzheimer's Disease — Are We on the Right Road? New England Journal of Medicine. 2014;370(4):377-378. doi:10.1056/NEJMe1313943

12.

Johnson KA, Fox NC, Sperling RA, Klunk WE. Brain Imaging in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine. 2012;2(4):a006213-a006213. doi:10.1101/cshperspect.a006213

13.

Ross CA, Aylward EH, Wild EJ, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nature Reviews Neurology. 2014;10(4):204-216. doi:10.1038/nrneurol.2014.24

14.

Bates GP, Dorsey R, Gusella JF, et al. Huntington disease. Nature Reviews Disease Primers. Published online 23 April 2015. doi:10.1038/nrdp.2015.5

15.

Wild EJ, Tabrizi SJ. Therapies targeting DNA and RNA in Huntington's disease. The Lancet Neurology. 2017;16(10):837-847. doi:10.1016/S1474-4422(17)30280-6

16.

Carroll JB, Bates GP, Steffan J, Saft C, Tabrizi SJ. Treating the whole body in Huntington's disease. The Lancet Neurology. 2015;14(11):1135-1142. doi:10.1016/S1474-4422(15)00177-5

17.

Tabrizi SJ, Scahill RI, Durr A, et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. The Lancet Neurology. 2011;10(1):31-42. doi:10.1016/S1474-4422(10)70276-3

18.

Tabrizi SJ, Reilmann R, Roos RA, et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. The Lancet Neurology. 2012;11(1):42-53. doi:10.1016/S1474-4422(11)70263-0

19.

Tabrizi SJ, Scahill RI, Owen G, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. *The Lancet Neurology*. 2013;12(7):637-649. doi:10.1016/S1474-4422(13)70088-7

20.

Jones L, Houlden H, Tabrizi SJ. DNA repair in the trinucleotide repeat disorders. *The Lancet Neurology*. 2017;16(1):88-96. doi:10.1016/S1474-4422(16)30350-7

21.

Rossor M, Collinge J, Fox N, et al. Dementia and Cognitive Impairment. In: Clarke C, Howard R, Rossor M, Shorvon S, eds. *Neurology*. John Wiley & Sons, Ltd; 2016:289-336. doi:10.1002/9781118486160.ch8

22.

Rossor MN, Fox NC, Mummery CJ, Schott JM, Warren JD. The diagnosis of young-onset dementia. *The Lancet Neurology*. 2010;9(8):793-806. doi:10.1016/S1474-4422(10)70159-9

23.

Schott JM, Fox NC, Rossor MN. Assessment and investigation of the cognitively impaired adult. In: Husain M, Schott JM, eds. *Oxford Textbook of Cognitive Neurology and Dementia*. Oxford University Press; 2016:221-230. doi:10.1093/med/9780199655946.003.0021

24.

Green AJE. RT-QulC: a new test for sporadic CJD. *Practical Neurology*. Published online 3 October 2018. doi:10.1136/practneurol-2018-001935

25.

Collinge J. Mammalian prions and their wider relevance in neurodegenerative diseases. *Nature*. 2016;539(7628):217-226. doi:10.1038/nature20415

26.

Mead S, Rudge P. CJD mimics and chameleons. *Practical Neurology*. 2017;17(2):113-121. doi:10.1136/practneurol-2016-001571

27.

Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. *The Lancet*. 2015;386(10004):1683-1697. doi:10.1016/S0140-6736(15)00462-6

28.

Halliday GM, Holton JL, Revesz T, Dickson DW. Neuropathology underlying clinical variability in patients with synucleinopathies. *Acta Neuropathologica*. 2011;122(2):187-204. doi:10.1007/s00401-011-0852-9

29.

Barker RA, Williams-Gray CH. Review: The spectrum of clinical features seen with alpha synuclein pathology. *Neuropathology and Applied Neurobiology*. 2016;42(1):6-19. doi:10.1111/nan.12303

30.

Bras J, Guerreiro R, Darwent L, et al. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. *Human Molecular Genetics*. 2014;23(23):6139-6146. doi:10.1093/hmg/ddu334

31.

McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies. *Neurology*. 2017;89(1):88-100. doi:10.1212/WNL.0000000000004058

32.

Weil RS, Lashley TL, Bras J, Schrag AE, Schott JM. Current concepts and controversies in the pathogenesis of Parkinson's disease dementia and Dementia with Lewy Bodies. *F1000Research*. 2017;6. doi:10.12688/f1000research.11725.1

33.

Woollacott IOC, Rohrer JD. The clinical spectrum of sporadic and familial forms of frontotemporal dementia. *Journal of Neurochemistry*. 2016;138:6-31. doi:10.1111/jnc.13654

34.

Gordon E, Rohrer JD, Fox NC. Advances in neuroimaging in frontotemporal dementia. *Journal of Neurochemistry*. 2016;138:193-210. doi:10.1111/jnc.13656

35.

Ahmed RM, Devenney EM, Irish M, et al. Neuronal network disintegration: common pathways linking neurodegenerative diseases. *Journal of Neurology, Neurosurgery & Psychiatry*. 2016;87(11):1234-1241. doi:10.1136/jnnp-2014-308350

36.

Fletcher PD, Warren JD. Semantic Dementia: a specific network-opathy. *Journal of Molecular Neuroscience*. 2011;45(3):629-636. doi:10.1007/s12031-011-9586-3

37.

Goll JC, Crutch SJ, Loo JHY, et al. Non-verbal sound processing in the primary progressive aphasia. *Brain*. 2010;133(1):272-285. doi:10.1093/brain/awp235

38.

Goll JC, Ridgway GR, Crutch SJ, Theunissen FE, Warren JD. Nonverbal sound processing in semantic dementia: A functional MRI study. *NeuroImage*. 2012;61(1):170-180. doi:10.1016/j.neuroimage.2012.02.045

39.

Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. *Neurology*. 2011;76(11):1006-1014.
doi:10.1212/WNL.0b013e31821103e6

40.

Grossman M. The non-fluent/agrammatic variant of primary progressive aphasia. *The Lancet Neurology*. 2012;11(6):545-555. doi:10.1016/S1474-4422(12)70099-6

41.

Leyton CE, Hodges JR, McLean CA, Kril JJ, Piguet O, Ballard KJ. Is the logopenic-variant of primary progressive aphasia a unitary disorder? *Cortex*. 2015;67:122-133.
doi:10.1016/j.cortex.2015.03.011

42.

Marshall CR, Hardy CJD, Volkmer A, et al. Primary progressive aphasia: a clinical approach. *Journal of Neurology*. 2018;265(6):1474-1490. doi:10.1007/s00415-018-8762-6

43.

Rohrer JD, Knight WD, Warren JE, Fox NC, Rossor MN, Warren JD. Word-finding difficulty: a clinical analysis of the progressive aphasias. *Brain*. 2007;131(1):8-38.
doi:10.1093/brain/awm251

44.

Rohrer JD, Ridgway GR, Crutch SJ, et al. Progressive logopenic/phonological aphasia: Erosion of the language network. *NeuroImage*. 2010;49(1):984-993.
doi:10.1016/j.neuroimage.2009.08.002

45.

Rohrer JD, Rossor MN, Warren JD. Syndromes of nonfluent primary progressive aphasia: A clinical and neurolinguistic analysis. *Neurology*. 2010;75(7):603-610.
doi:10.1212/WNL.0b013e3181ed9c6b

46.

Rohrer JD, Sauter D, Scott S, Rossor MN, Warren JD. Receptive prosody in nonfluent primary progressive aphasia. *Cortex*. 2012;48(3):308-316.
doi:10.1016/j.cortex.2010.09.004

47.

Warren JD, Rohrer JD, Rossor MN. Frontotemporal dementia. *BMJ*. 2013;347(aug12 3):f4827-f4827. doi:10.1136/bmj.f4827

48.

Lynch DS, Rodrigues Brandão de Paiva A, Zhang WJ, et al. Clinical and genetic characterization of leukoencephalopathies in adults. *Brain*. 2017;140(5):1204-1211.
doi:10.1093/brain/awx045

49.

Hollak CEM, Lachmann R, eds. *Inherited Metabolic Disease in Adults: A Clinical Guide*. Oxford University Press; 2016.
http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=3043210560004761&institutionId=4761&customerId=4760

50.

Devenney E, Vucic S, Hodges JR, Kiernan MC. Motor neuron disease-frontotemporal dementia: a clinical continuum. *Expert Review of Neurotherapeutics*. 2015;15(5):509-522.
doi:10.1586/14737175.2015.1034108

51.

Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*. 2017;18(3-4):153-174.
doi:10.1080/21678421.2016.1267768

52.

Iranzo A, Fernández-Arcos A, Tolosa E, et al. Neurodegenerative Disorder Risk in Idiopathic REM Sleep Behavior Disorder: Study in 174 Patients. PLoS ONE. 2014;9(2). doi:10.1371/journal.pone.0089741

53.

Kielb SA, Ancoli-Israel S, Rebok GW, Spira AP. Cognition in Obstructive Sleep Apnea-Hypopnea Syndrome (OSAS): Current Clinical Knowledge and the Impact of Treatment. NeuroMolecular Medicine. 2012;14(3):180-193. doi:10.1007/s12017-012-8182-1

54.

Mander BA, Winer JR, Jagust WJ, Walker MP. Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer's Disease? Trends in Neurosciences. 2016;39(8):552-566. doi:10.1016/j.tins.2016.05.002

55.

McCarter SJ, St. Louis EK, Boeve BF. Sleep Disturbances in Frontotemporal Dementia. Current Neurology and Neuroscience Reports. 2016;16(9). doi:10.1007/s11910-016-0680-3

56.

Ooms S, Ju YE. Treatment of Sleep Disorders in Dementia. Current Treatment Options in Neurology. 2016;18(9). doi:10.1007/s11940-016-0424-3

57.

Hardy CJD, Marshall CR, Golden HL, et al. Hearing and dementia. Journal of Neurology. 2016;263(11):2339-2354. doi:10.1007/s00415-016-8208-y

58.

Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. The Lancet. 2017;390(10113):2673-2734. doi:10.1016/S0140-6736(17)31363-6

59.

Goll JC, Crutch SJ, Warren JD. Central auditory disorders: toward a neuropsychology of auditory objects. *Current Opinion in Neurology*. 2010;23(6):617-627.
doi:10.1097/WCO.0b013e32834027f6

60.

Husain M. *Oxford Textbook of Cognitive Neurology and Dementia*. (Husain M, Schott JM, Kennard C, eds.). Oxford University Press; 2016.
http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=3119511110004761&institutionId=4761&customerId=4760

61.

Blennow K, Hardy J, Zetterberg H. The Neuropathology and Neurobiology of Traumatic Brain Injury. *Neuron*. 2012;76(5):886-899. doi:10.1016/j.neuron.2012.11.021

62.

Smith DH, Johnson VE, Stewart W. Chronic neuropathologies of single and repetitive TBI: substrates of dementia? *Nature Reviews Neurology*. 2013;9(4):211-221.
doi:10.1038/nrneurol.2013.29

63.

McKee AC, Stein TD, Nowinski CJ, et al. The spectrum of disease in chronic traumatic encephalopathy. *Brain*. 2013;136(1):43-64. doi:10.1093/brain/aws307

64.

Fleminger S. Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replication. *Journal of Neurology, Neurosurgery & Psychiatry*. 2003;74(7):857-862.
doi:10.1136/jnnp.74.7.857

65.

Scott G, Ramlackhansingh AF, Edison P, et al. Amyloid pathology and axonal injury after brain trauma. *Neurology*. 2016;86(9):821-828. doi:10.1212/WNL.0000000000002413

66.

Hereditary and sporadic beta-amyloidoses.
<https://www.bioscience.org/2013/v18/af/4173/fulltext.htm>

67.

Johnson GVW. Tau phosphorylation in neuronal cell function and dysfunction. *Journal of Cell Science*. 2004;117(24):5721-5729. doi:10.1242/jcs.01558

68.

Revesz T, Holton JL, Lashley T, et al. Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. *Acta Neuropathologica*. 2009;118(1):115-130. doi:10.1007/s00401-009-0501-8

69.

Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. *Acta Neuropathologica*. 2012;123(1):1-11. doi:10.1007/s00401-011-0910-3

70.

Thal DR. Neurodegeneration in Normal Brain Aging and Disease. *Science of Aging Knowledge Environment*. 2004;2004(23):pe26-pe26. doi:10.1126/sageke.2004.23.pe26

71.

Braak H, Braak E. Staging of alzheimer's disease-related neurofibrillary changes. *Neurobiology of Aging*. 1995;16(3):271-278. doi:10.1016/0197-4580(95)00021-6

72.

Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for

Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. *Neurology*. 1991;41(4):479-479. doi:10.1212/WNL.41.4.479

73.

Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. *Acta Neuropathologica*. 2012;123(1):1-11. doi:10.1007/s00401-011-0910-3

74.

Dobson R, Alvares D. The difficulties with vitamin B. *Practical Neurology*. 2016;16(4):308-311. doi:10.1136/practneurol-2015-001344

75.

Jonathan Carr. Neurosyphilis. *Practical Neurology*. 2003;3:328-341.
<https://pn.bmj.com/content/3/6/328>

76.

Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. *The Lancet Neurology*. 2016;15(4):391-404.
doi:10.1016/S1474-4422(15)00401-9

77.

Salvarani C, Brown RD, Hunder GG. Adult primary central nervous system vasculitis. *The Lancet*. 2012;380(9843):767-777. doi:10.1016/S0140-6736(12)60069-5

78.

Halperin JJ, Kurlan R, Schwalb JM, Cusimano MD, Gronseth G, Gloss D. Practice guideline: Idiopathic normal pressure hydrocephalus: Response to shunting and predictors of response. *Neurology*. 2015;85(23):2063-2071. doi:10.1212/WNL.0000000000002193

79.

Arash Asher. The effect of cancer treatment on cognitive function. undefined.
<https://www.semanticscholar.org/paper/The-effect-of-cancer-treatment-on-cognitive-Asher-Myers/6bdd550dab6cfad0714aa76dd2ee439ad983e4be>

80.

Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. *The Lancet Neurology*. 2016;15(4):391-404.
doi:10.1016/S1474-4422(15)00401-9

81.

Cognitive Impairment Associated with Cancer: A Brief Review. *Innovations in Clinical Neuroscience*. 2018;15(1-2). <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819720/>

82.

Haddow LJ, Cartledge JD, Manji H. HIV and the brain: from AIDS to old age. *Clinical Medicine*. 2013;13(Suppl_6):s24-s28. doi:10.7861/clinmedicine.13-6-s24

83.

Nightingale S, Michael BD, Defres S, Benjamin LA, Solomon T. Test them all; an easily diagnosed and readily treatable cause of dementia with life-threatening consequences if missed. *Practical Neurology*. 2013;13(6):354-356. doi:10.1136/practneurol-2013-000689

84.

HIV in the United Kingdom 2016 infographic.
<https://www.gov.uk/government/publications/hiv-in-the-united-kingdom>

85.

Itzhaki RF, Lathe R, Balin BJ, et al. Microbes and Alzheimer's Disease. *Journal of Alzheimer's Disease*. 2016;51(4):979-984. doi:10.3233/JAD-160152

86.

Nightingale S, Winston A, Letendre S, et al. Controversies in HIV-associated neurocognitive disorders. *The Lancet Neurology*. 2014;13(11):1139-1151.
doi:10.1016/S1474-4422(14)70137-1

87.

Richard W. Price and Bruce J. Brew. The AIDS Dementia Complex. *The Journal of Infectious Diseases*. 1988;158(5).
https://www.jstor.org/stable/30136610?seq=1#metadata_info_tab_contents

88.

UK National Guidelines for HIV Testing 2008. <https://www.bhiva.org/HIV-testing-guidelines>

89.

Zhou L, Miranda-Saksena M, Saksena NK. Viruses and neurodegeneration. *Virology Journal*. 2013;10(1). doi:10.1186/1743-422X-10-172

90.

De Chiara G, Marcocci ME, Sgarbanti R, et al. Infectious Agents and Neurodegeneration. *Molecular Neurobiology*. 2012;46(3):614-638. doi:10.1007/s12035-012-8320-7

91.

Wendorf KA, Winter K, Zipprich J, et al. Subacute Sclerosing Panencephalitis: The Devastating Measles Complication That Might Be More Common Than Previously Estimated. *Clinical Infectious Diseases*. 2017;65(2):226-232. doi:10.1093/cid/cix302

92.

Ghanem KG. REVIEW: Neurosyphilis: A Historical Perspective and Review. *CNS Neuroscience & Therapeutics*. 2010;16(5):e157-e168.
doi:10.1111/j.1755-5949.2010.00183.x

93.

Somasundaram O. Neuro syphilis: Portrayals by Sir Arthur Conan Doyle. *Indian Journal of Psychiatry*. 2009;51(3). doi:10.4103/0019-5545.55103

94.

Hachinski V, Iadecola C, Petersen RC, et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards. *Stroke*. 2006;37(9):2220-2241. doi:10.1161/01.STR.0000237236.88823.47

95.

Gorelick PB, Scuteri A, Black SE, et al. Vascular Contributions to Cognitive Impairment and Dementia. *Stroke*. 2011;42(9):2672-2713. doi:10.1161/STR.0b013e3182299496

96.

Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. *The Lancet*. 2001;357(9251):169-175. doi:10.1016/S0140-6736(00)03589-3

97.

Leys D, Hénon H, Mackowiak-Cordoliani MA, Pasquier F. Poststroke dementia. *The Lancet Neurology*. 2005;4(11):752-759. doi:10.1016/S1474-4422(05)70221-0

98.

O'Brien JT, Thomas A. Vascular dementia. *The Lancet*. 2015;386(10004):1698-1706. doi:10.1016/S0140-6736(15)00463-8